Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Background: Treatment of rheumatoid arthritis (RA) includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs) and oral, intramuscularly, intravenous, or intraarticular (IA) glucocorticoids (GCs). In this paper, we analysed whether a treat-to-target (T2T) stra...

Full description

Bibliographic Details
Main Authors: Ruediger B. Mueller, Michael Spaeth, Cord von Restorff, Christoph Ackermann, Hendrik Schulze-Koops, Johannes von Kempis
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Journal of Clinical Medicine
Subjects:
rheumatoid arthritis
treat-to-target
certolizumab pegol
csDMARDs
glucocorticoids
intra-articular injections
DAS 28
ACR response
HAQ-DI
Online Access:http://www.mdpi.com/2077-0383/8/3/302

Internet

http://www.mdpi.com/2077-0383/8/3/302

Similar Items